EU/3/20/2390: Orphan designation for the treatment of idiopathic pericarditis



On 6 January 2021, orphan designation EU/3/20/2390 was granted by the European Commission to Granzer Regulatory Consulting & Services, Germany, for rilonacept for the treatment of idiopathic pericarditis.

The sponsorship was transferred to Blue-Reg Pharma Consult, France in April 2022.

Key facts

Active substance
Intended use
Treatment of idiopathic pericarditis
Orphan designation status
EU designation number
Date of designation

Yes Pharmaceutical Development Services GmbH
Bahnstrasse 42-46

61381 Friedrichsdorf




Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Update history

Date Update

January 2023

The sponsorship was transferred from Blue-Reg Pharma Consult, France to Yes Pharmaceutical Development Services GmbH, Germany

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating